Patent · US Expired

Modified peptide

US7402663B2 · kind B2 · utility

3Cited by

3References

4Claims

0Family size

Assignee

University of Ulster · GB

Inventors

Peter Raymond Flatt · Portstewart, GB
Finbarr Paul Mary O'Harte · Ballymoney, GB

Key dates

Filing date	Feb 28, 2002
Grant date	Jul 22, 2008
Priority date	—
Expiry date	Jul 12, 2023

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K38/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention provides a peptide based on biologically active CCK-8 having improved characteristics for the treatment of obesity and/or type 2 diabetes wherein the primary structure of CCK-8 is: Asp1Tyr2(SO3H)-Met3Gly4Trp5Met6Asp7Phe8amide (SEQ ID NO:1) and wherein the peptide has at least one amino add substitution and/or modification and is not Asp1-glucitol CCK-8. The invention also provides the use of the peptide in the preparation of a medicament to inhibit food intake, induce satiety, stimulate insulin secretion, moderate blood glucose excursions, enhance glucose disposal and/or exhibit enhanced stability in plasma compared to native CCK-8 and/or for treatment of obesity and/or type 2 diabetes.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.